Brain Cancer Clinical Trials in Detroit

Showing 141-160 of 174 trials

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma

NCT01122901

This phase II trial is studying how well gamma-secretase/Notch signalling pathway inhibitor RO4929097 works in treating patients with recurrent or progressive glioblastoma. Gamma-secretase/Notch signalling pathway inhibitor RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Adult Giant Cell GlioblastomaAdult GlioblastomaAdult Gliosarcoma+1 more

National Cancer Institute (NCI)47 participantsStarted Dec 2010

Atlanta, Georgia, United States • Detroit, Michigan, United States • Cleveland, Ohio, United States +2 more locations

COMPLETEDPhase 3< 1 mile

Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

NCT00916409

The study is a prospective, randomly controlled pivotal trial, designed to test the efficacy and safety of a medical device, the NovoTTF-100A, as an adjuvant to the best standard of care in the treatment of newly diagnosed GBM patients. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.

Glioblastoma Multiforme

NovoCure Ltd.700 participantsStarted Jun 2009

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Duarte, California, United States +86 more locations

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma

Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

Brain Cancer Trials in Other Cities

A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme

Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma

Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Brain Stem Glioma

Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma

Gene Testing to Help in the Diagnosis and Treatment of Childhood Brain Tumors

Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme

Pazopanib in Treating Patients With Recurrent Glioblastoma

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma

AMG 595 First-in-Human in Recurrent Gliomas

A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma

MK-2206 for Recurrent Malignant Glioma

A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma

Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme

Other Conditions in Detroit